Australian Pharmaceutical Industries Limited (ASX:API) revealed its results for the half year ending 29 February 2020 and mentioned that the Company delivered in line with expectations.
- Total revenue was reported to be $2.0 billion, up by 2.8% on the prior corresponding period (pcp);
- Reported EBIT stood at $39.3 million, down by 11.5% on the pcp;
- The Company’s Reported NPAT was at $22.5 million, down by 9.9% on the pcp.
Moreover, the Company’s focus is on cash management and assets positioned to sustain through the ongoing COVID-19 pandemic.